PHAXIAM Therapeutics SA (NAS:PHXM)
$ 3.1 -0.02 (-0.64%) Market Cap: 18.82 Mil Enterprise Value: 18.82 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q2 2021 Erytech Pharma SA Earnings Call Transcript

Sep 21, 2021 / 12:30PM GMT
Release Date Price: $61.5 (-3.76%)
Operator

Good day, and thank you for standing by. Welcome to the ERYTECH business update and financial highlights for the second quarter of year 2021. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I'd now like to hand the conference over to your speaker today, Gil Beyen, Chief Executive Officer. Please go ahead.

Gil Beyen
ERYTECH Pharma S.A. - CEO

Thank you, Liz, and good afternoon. Good morning. (Spoken in French) Thank you for joining us for our earnings call to discuss the highlights and financials for the first half of this year. I hope everyone is well and safe today wherever you may be taking today's call.

We announced our business and financial update yesterday evening, September 20. The press release and the first-half earnings presentation can be found on the -- in the Investor sections of our website.

Joining me here today on this call are Dr. Iman El-Hariry, our Chief Medical Officer, together with me here in Boston; and Eric Soyer, our Chief Financial and Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot